Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial irinotecan liposome plus S-1 for previously treated metastatic pancreatic cancer with liver metastases
ChiCTR2400091274Phase 2Not yet recruiting
- Sponsor
- Department of Integrative Medicine, Fudan University Shanghai Cancer Center
- Start
- Oct 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome and tegafur in pancreatic adenocarcinoma (PDAC), sponsored by Department of Integrative Medicine, Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
irinotecan liposometegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400091274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091274.